The nodes of pathogenesis of T2DM become targets of the invention of antihyperglycemic drugs, such as insulin secretagogues, insulin sensitizer agents, α-glucosidase inhibitors, GLP-1 analogs, and DPP-4 inhibitors. The gene discussed is GCG; the disease is type 2 diabetes mellitus.